Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 5/20 | 0.49 |
| ▸ | FLT4 | P35916 | 3/20 | 0.49 |
| ▸ | CSF1R | P07333 | 2/20 | 0.49 |
| ▸ | FLT3 | P36888 | 2/20 | 0.49 |
| ▸ | KDR | P35968 | 9/20 | 0.47 |
| ▸ | EGFR | P00533 | 4/20 | 0.47 |
| ▸ | BRAF | P15056 | 3/20 | 0.47 |
| ▸ | RET | P07949 | 2/20 | 0.46 |
| ▸ | RAF1 | P04049 | 3/20 | 0.45 |
| ▸ | FLT1 | P17948 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5828886 | 1.00 | PDGFRB (0.49) | PDGFRBFLT4CSF1RFLT3KDR | |
| SCHEMBL5828140 | 0.94 | EGFR (0.50) | PDGFRBKDREGFRBRAFRET | |
| SCHEMBL5828139 | 0.94 | EGFR (0.50) | PDGFRBKDREGFRBRAFRET | |
| SCHEMBL5828263 | 0.91 | PDGFRB (0.52) | PDGFRBFLT4CSF1RFLT3KDR | |
| SCHEMBL5828257 | 0.91 | PDGFRB (0.52) | PDGFRBFLT4CSF1RFLT3KDR | |
| SCHEMBL5828930 | 0.88 | PDGFRB (0.46) | PDGFRBFLT4CSF1RFLT3KDR | |
| SCHEMBL5828927 | 0.88 | PDGFRB (0.46) | PDGFRBFLT4CSF1RFLT3KDR | |
| SCHEMBL7091634 | 0.87 | KDR (0.54) | PDGFRBFLT4CSF1RFLT3KDR | |
| SCHEMBL5828194 | 0.86 | RAF1 (0.48) | FLT4KDREGFRRETRAF1 | |
| SCHEMBL5828196 | 0.86 | RAF1 (0.48) | FLT4KDREGFRRETRAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7001904-B1 | Guanidine derivatives quinazoline and quinoline for use in the treatment of autoimmune diseases | ASTRAZENECA AB (SE) | 2006-02-21 | — | — | US | disclosed |
| EP-1296973-A1 | GUANIDINE DERIVATIVES OF QUINAZOLINE AND QUINOLINE FOR USE IN THE TREATMENT OF AUTOIMMUNE DISEASES | AstraZeneca AB (SE) | 2003-04-02 | — | — | EP | disclosed |
| WO-2002000644-A1 | GUANIDINE DERIVATIVES OF QUINAZOLINE AND QUINOLINE FOR USE IN THE TREATMENT OF AUTOIMMUNE DISEASES | ASTRAZENECA AB (SE) | 2002-01-03 | — | — | WO | disclosed |